ArticleJournal of cancer research and clinical oncology2020

Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.

Jing Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.